Selective peroxisome proliferator-activated receptor δ isosteric selenium agonists as potent anti-atherogenic agents in vivo

被引：9

作者：

Chin, Jungwook ^{[1
]}

Hong, Jun Young ^{[1
]}

Lee, Jaehwan ^{[1
]}

Hwang, Hoosang ^{[1
]}

Ko, Hyunsil ^{[1
]}

Choi, Hyukjae ^{[1
]}

Hahn, Dongyup ^{[1
]}

Ko, Jaeyoung ^{[1
]}

Nam, Sang-Jip ^{[1
]}

Tak, Jungae ^{[1
]}

Ham, Jungyeob ^{[2
]}

Kang, Heonjoong ^{[1
,3
]}

机构：

[1] Seoul Natl Univ, Sch Earth & Environm Sci, Ctr Marine Nat Prod & Drug Discovery, Seoul 151747, South Korea

[2] Korea Inst Sci & Technol, Kangnung 210340, South Korea

[3] SNU, Res Inst Oceanog, Seoul 151741, South Korea

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 24期

关键词：

PPAR delta-selective ligand; Anti-atherogenic agents; Intestinal polyp formation; PPAR-DELTA; MOLECULAR MODIFICATION; ATHEROSCLEROSIS; CHOLESTEROL; SULFIDES; BIOISOSTERISM; BETA/DELTA; MODELS; HEART; MICE;

D O I：

10.1016/j.bmcl.2010.10.103

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report the synthesis and in vivo activity of a novel anti-atherogenic agent, isosteric selenium PPAR delta-selective ligand. This ligand did not cause significant body or liver weight changes and did not have obvious adverse effects on intestinal polyp formation. Our overall results clearly demonstrate that PPAR delta is a viable drug candidate for targeting and treating atherosclerosis. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：7239 / 7242

页数：4

共 50 条

[41] The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists Reply
Friedland, Sayuri
Filion, Kristian B.
Eisenberg, Mark J.
AMERICAN JOURNAL OF MEDICINE, 2013, 126 (03): : E13 - E13
[42] Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor γ indole partial agonists
Eeda, Venkateswararao
Wu, Dan
Lim, Hui-Ying
Wang, Weidong
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (22)
[43] Tributyltin is a potent inhibitor of piscine peroxisome proliferator-activated receptor α and β
Colliar, Louise
Sturm, Armin
Leaver, Michael J.
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY, 2011, 153 (01): : 168 - 173
[44] Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents
Kopelovich, L
Fay, JR
Glazer, RI
Crowell, JA
MOLECULAR CANCER THERAPEUTICS, 2002, 1 (05) : 357 - 363
[45] Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists
Kim, Sae On
Han, Yujia
Ahn, Sungjin
An, Seungchan
Shin, Jeayoung C.
Choi, Hyunjung
Kim, Hyoung-June
Park, Nok Hyun
Kim, Yong-Jin
Jin, Sun Hee
Rho, Ho Sik
Noh, Minsoo
BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (21) : 5654 - 5663
[46] Cardioprotective effects of thiazolidinediones, peroxisome proliferator-activated receptor-γ agonists
Yue, TL
DRUGS OF TODAY, 2003, 39 (12) : 949 - 960
[47] Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney
Speeckaert, Marijn M.
Vanfraechem, Celine
Speeckaert, Reinhart
Delanghe, Joris R.
AGEING RESEARCH REVIEWS, 2014, 14 : 1 - 18
[48] Peroxisome Proliferator-Activated Receptor Agonists Inhibit Inflammatory Edema and Hyperalgesia
Bradley K. Taylor
Niren Dadia
Carolyn B. Yang
Sendhil Krishnan
Mostafa Badr
Inflammation, 2002, 26 : 121 - 127
[49] Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders
Sagheddu, Claudia
Melis, Miriam
Muntoni, Anna Lisa
Pistis, Marco
PHARMACEUTICALS, 2021, 14 (10)
[50] Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?
Blaschke, F
Bruemmer, D
Law, RE
CLINICAL CARDIOLOGY, 2004, 27 (07) : 3 - 10

← 1 2 3 4 5 →